Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) Shares Outstanding (Diluted Average) (2019 - 2023)

Historic Shares Outstanding (Diluted Average) for CytomX Therapeutics (CTMX) over the last 5 years, with Q4 2023 value amounting to $73.8 million.

  • CytomX Therapeutics' Shares Outstanding (Diluted Average) rose 1227.32% to $73.8 million in Q4 2023 from the same period last year, while for Dec 2023 it was $73.8 million, marking a year-over-year increase of 1227.32%. This contributed to the annual value of $73.8 million for FY2023, which is 1227.32% up from last year.
  • Latest data reveals that CytomX Therapeutics reported Shares Outstanding (Diluted Average) of $73.8 million as of Q4 2023, which was up 1227.32% from $66.5 million recorded in Q2 2023.
  • In the past 5 years, CytomX Therapeutics' Shares Outstanding (Diluted Average) registered a high of $73.8 million during Q4 2023, and its lowest value of $45.3 million during Q4 2019.
  • Its 5-year average for Shares Outstanding (Diluted Average) is $59.8 million, with a median of $65.3 million in 2021.
  • In the last 5 years, CytomX Therapeutics' Shares Outstanding (Diluted Average) skyrocketed by 4125.09% in 2021 and then soared by 67.97% in 2022.
  • CytomX Therapeutics' Shares Outstanding (Diluted Average) (Quarter) stood at $45.3 million in 2019, then rose by 2.79% to $46.6 million in 2020, then skyrocketed by 40.12% to $65.3 million in 2021, then grew by 0.68% to $65.7 million in 2022, then increased by 12.27% to $73.8 million in 2023.
  • Its Shares Outstanding (Diluted Average) stands at $73.8 million for Q4 2023, versus $66.5 million for Q2 2023 and $66.2 million for Q1 2023.